Prediction of Pharmacokinetics of Repeat Dosing of Dihydroergotamine Mesylate Via Precision Olfactory Delivery (INP104) for the Acute Treatment of Migraine

被引：0
|
作者：
Aurora, Sheena [1 ]
Robblee, Jennifer [2 ]
Mathew, Paul G. [2 ,3 ,4 ,5 ]
Vann, Robert E. [1 ]
Ray, Sutapa [1 ]
Hoekman, John [1 ]
机构：
[1] Impel Pharmaceut, Seattle, WA USA
[2] Barrow Neurol Inst, Phoenix, AZ 85013 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Mass Gen Brigham Hlth, Foxboro, MA USA
[5] Harvard Vanguard Med Associates, Braintree, MA USA
来源：
CEPHALALGIA | 2023年 / 43卷 / 1supp期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC23-PO-2
引用
收藏
页码：218 / 219
页数：2
相关论文
共 16 条
  • [1] Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine
    Dafer, Rima M.
    Tietjen, Gretchen E.
    Rothrock, John F.
    Vann, Robert E.
    Shrewsbury, Stephen B.
    Aurora, Sheena K.
    HEADACHE, 2024, 64 (08): : 983 - 994
  • [2] Early prediction of response to INP104 for the acute treatment of migraine
    Sacco, S.
    Vann, R.
    Lieu, T.
    Ray, S.
    Shrewsbury, S. B.
    Aurora, S. K.
    HEADACHE, 2022, 62 : 127 - 128
  • [3] STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(R)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
    Smith, Timothy R.
    Winner, Paul
    Aurora, Sheena K.
    Jeleva, Maria
    Hocevar-Trnka, Jasna
    Shrewsbury, Stephen B.
    HEADACHE, 2021, 61 (08): : 1214 - 1226
  • [4] INP104: a drug evaluation of a nonoral product for the acute treatment of migraine
    Starling, Amaal J.
    Mallick-Searle, Theresa
    Shrewsbury, Stephen B.
    Aurora, Sheena K.
    PAIN MANAGEMENT, 2023, 13 (05) : 283 - 298
  • [5] STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (PODTM) Device] in Migraine Headache
    Shrewsbury, Stephen B.
    Jeleva, Maria
    Hocevar-Trnka, Jasna
    Swardstrom, Meghan
    CEPHALALGIA, 2019, 39 : 208 - 209
  • [6] STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (POD®) Device] in Migraine Headache
    Shrewsbury, S. B.
    Jeleva, M.
    Swardstrom, M.
    HEADACHE, 2019, 59 : 53 - 54
  • [7] Precision Olfactory Delivery (POD®) of Drugs for Neurological Disease: A Safety, Tolerability and Comparative Bioavailability Study of POD Dihydroergotamine Mesylate (INP104) to Approved IV DHE 45® and Migranal® Nasal Spray
    Shrewsbury, Stephen
    Jeleva, Maria
    Lickliter, Jason
    Satterly, Kelsey
    Hoekman, John
    NEUROLOGY, 2019, 92 (15)
  • [8] PATIENT ACCEPTABILITY OF A NOVEL UPPER NASAL DELIVERY SYSTEM FOR DHE - USING THE PRECISION OLFACTORY DELIVERY (PODVR) DEVICE (INP104)
    Shrewsbury, Stephen
    Aurora, Sheena
    Hoekman, John
    Jeleva, Maria
    CEPHALALGIA, 2020, 40 : 43 - 44
  • [9] Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
    Cooper, Wade
    Ray, Sutapa
    Aurora, Sheena K.
    Shrewsbury, Stephen B.
    Fuller, Christopher
    Davies, Greg
    Hoekman, John
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2022, 35 (06) : 321 - 332
  • [10] STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD®) Device, in Healthy Adult Subjects
    Shrewsbury, Stephen B.
    Jeleva, Maria
    Satterly, Kelsey H.
    Lickliter, Jason
    Hoekman, John
    HEADACHE, 2019, 59 (03): : 394 - 409
12